Physician profile
Daniel Philip Kellar
NPI 1467443119
$5,611.97
in general payments reported to CMS, 2019-2025
38 companies · $891 in 2025
The $891 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $776 · 2020: $435 · 2021: $716 · 2022: $635 · 2023: $945 · 2024: $1,215 · 2025: $891.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,050.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $973.53 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $881.59 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $793.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $761.12 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $365.98 | 2021-2025 | |
| Pfizer INC. | $222.89 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $148.94 | 2019-2024 | |
| Abbott Laboratories | $144.56 | 2022-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $143.18 | 2021-2025 | |
| Amgen INC. | $140.15 | 2022-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.82 | 2019-2024 | Ofev, Jardiance |
| Exact Sciences Corporation | $131.33 | 2023-2025 | Cologuard Collection Kit |
| Dexcom, INC. | $115.37 | 2021-2023 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $60.55 | 2019-2023 | |
| Grifols USA, LLC | $50.32 | 2019-2020 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Kellar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.